Dr. Stephen G O'Brien - CML - Chronic myeloid leukemia

" Stephen O'Brien is a Professor of Haematology at Newcastle University and Honorary Consultant in Haematology at the Newcastle upon Tyne Hospitals NHS Foundation Trust. Following graduation and internal medical experience in Manchester, his training in haematology was undertaken at the Hammersmith Hospital in London where he subsequently completed his PhD under Professor John Goldman. He then worked in Cardiff before settling in Newcastle. He treated the first UK patients to receive Imatinib in September 1999, and continues to be closely involved with ongoing trials with this agent, as well as the newer Tyrosine Kinase Inhibitors. Professor O’Brien is the Chief Investigator for the National Cancer Research Network’s SPIRIT trials in Chronic Myeloid Leukaemia (www.spirit-cml.org), involving approximately 2,000 patients in 150 UK hospitals. Also, he is a member of the NCRI Haem Onc Clinical Studies Group and CML Working Party and the European Leukaemia Network and Vice Chair of NICE Technology Appraisal Committee C."
​Extract of  Northern Institute for Cancer Research, Newcastle University

Other links:    Stephen G O'Brien's scientific contributions while affiliated with Newcastle University 
                              Some publications with Dr. G O'Brien
                              Some presentations and notes from ASH meetings
​                                       

VIDEOS

Outlook for the management of chronic myeloid leukemia
July 10, 2015,  VJHemOnc – Video Journal of Hematological Oncology

​
ARTICLES
​
Chronic myeloid leukemia: an overview of data from American Society of Hematology 2014
November 21, 2014, Rev Hematol Mex

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.
November 17, 2003, Pubmed
​
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
April 2003, Pubmed

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
March 13, 2003, Pubmed
​
Position paper on imatinib mesylate in chronic myeloid leukaemia
October 2, 2002, British Journal Of Haematology

Chronic myelogenous leukemia
January 1, 2002, ASH education book
​